Anavex Life Sciences Corp (AVXL)

[falconer66a]

Another Anavex CNS indication — stroke.

Interesting paper. Wish I could read the whole thing.

But it’s an Elsevier publication. That publisher charges for access to entire papers, beyond the posted abstract.

https://pubmed.ncbi.nlm.nih.gov/34582837/

First, if sigma-1 receptor activation does alleviate the blood–brain barrier disruption caused by cerebral ischemia strokes, there is a gigantic market for this; and hundreds of thousands to millions of stroke patients would benefit profoundly.

But, because I couldn’t read the actual paper, I could not read the details of how this was determined. What was the specific sigma-1 receptor agonist used in the study? Could it have been as good as blarcamesine or Anavex 3-71? What was the dosing regimen? What were the therapeutic results? How were they assessed?

Once again, yet another CNS disease or condition ameliorated by sigma-1 receptor activation. So far, no other drugs have matched the safety and therapeutic outcomes of blarcamesine or Anavex 3-71.

Let’s now see a clinical trial with our drugs, for ischemic strokes; first, as in this study, in mice. Then, real humans.